Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and early trials suggest very strong ...
Ozempic has been approved for type-2 diabetes, while Novo Nordisk’s other global blockbuster Wegovy is targeted at obesity.
The managing director of Novo Nordisk India on Ozempic’s delayed launch in India, leading the fight against diabetes and ...
In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...
The Delhi High Court ruled against Novo Nordisk's request to block Dr Reddy's production of semaglutide for export. The case ...
The Chosun Ilbo on MSN
Wegovy use linked to reduced alcohol, tobacco spending
A study has found that Novo Nordisk’s obesity treatment ‘Wegovy’ also impacted household spending on alcohol and tobacco.
A Division Bench of Delhi High Court on Friday declined to stay a Single Judge’s order that had allowed Dr Reddy’s ...
India may be embracing GLP-1 weight-loss drugs, but healthtech startup Fittr is standing against the trend. With the launch ...
The city of Springfield, Drew Lewis Foundation, Catholic Charities of Southern Missouri, Habitat for Humanity of Springfield, ...
As guys who value our health, and like the millions of Americans who voted for Donald Trump because he promised to help Make ...
A proposed new federal law could provide some competitive guardrails for the company's most important product.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback